STOCK TITAN
  1. Home
  2. Sec-filings
  3. STOK
  4. [Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

Stoke Therapeutics (STOK) CMO sells 7,176 shares under 10b5-1 plan

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. chief medical officer Barry Ticho reported selling 7,176 shares of common stock on August 3, 2026 in two open-market or private transactions, at weighted-average prices of $28.9501 and $29.4539 per share, under a Rule 10b5-1 trading plan adopted on November 19, 2025. The sales occurred in price ranges of $28.36–$29.35 and $29.36–$29.54 per share, respectively.

Positive

  • None.

Negative

  • None.
Insider Ticho Barry
Role CHIEF MEDICAL OFFICER
Sold 7,176 shs ($208K)
Type Security Shares Price Value
Sale Common Stock F1, F2 5,907 $28.9501 $171K
Sale Common Stock F1, F3 1,269 $29.4539 $37K
Holdings After Transaction: Common Stock — 20,422 shares (Direct)
Footnotes (3)
  1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
  2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.36 to $29.35 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
  3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.36 to $29.54 per share, inclusive.
Total shares sold 7,176 shares Aggregate common shares sold by CMO Barry Ticho on August 3, 2026
Shares sold (block 1) 5,907 shares First sale of common stock on August 3, 2026
Weighted-average sale price (block 1) $28.9501 per share Average price for 5,907 shares sold within a $28.36–$29.35 range
Price range (block 1) $28.36–$29.35 per share Range of prices for 5,907 shares sold on August 3, 2026
Shares sold (block 2) 1,269 shares Second sale of common stock on August 3, 2026
Weighted-average sale price (block 2) $29.4539 per share Average price for 1,269 shares sold within a $29.36–$29.54 range
Price range (block 2) $29.36–$29.54 per share Range of prices for 1,269 shares sold on August 3, 2026
Rule 10b5-1 plan adoption date November 19, 2025 Adoption date of Barry Ticho’s trading plan governing these sales
Rule 10b5-1 trading plan financial
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The reported price in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open market or private transaction financial
"Sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transaction did Stoke Therapeutics (STOK) disclose?
Stoke Therapeutics reported that chief medical officer Barry Ticho sold 7,176 shares of common stock on August 3, 2026. The sale occurred in two open-market or private transactions at weighted-average prices of $28.9501 and $29.4539 per share under a Rule 10b5-1 trading plan.

How many Stoke Therapeutics (STOK) shares did Barry Ticho sell and at what price ranges?
Barry Ticho sold 5,907 shares at a weighted-average price of $28.9501 within a $28.36–$29.35 range. He also sold 1,269 shares at a weighted-average price of $29.4539 within a $29.36–$29.54 range, all on August 3, 2026.

Was the Stoke Therapeutics (STOK) insider sale made under a Rule 10b5-1 plan?
Yes. The filing states the transactions were executed under a Rule 10b5-1 trading plan adopted by Barry Ticho on November 19, 2025. Such plans allow pre-arranged stock trades according to preset instructions, independent of subsequent inside information.

What is Barry Ticho’s role at Stoke Therapeutics (STOK)?
Barry Ticho is identified as the company’s chief medical officer. The reported Form 4 shows him as the sole reporting person, with the August 3, 2026 transactions involving his direct ownership of Stoke Therapeutics common stock, as indicated by the direct ownership code.

How many separate transactions comprised the August 3, 2026 sale of Stoke Therapeutics (STOK) shares?
The sale consisted of two separate non-derivative transactions in common stock. One block covered 5,907 shares at a weighted-average price of $28.9501, and a second block covered 1,269 shares at a weighted-average price of $29.4539, both sold on the same date.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ticho Barry
(Last)(First)(Middle)
C/O STOKE THERAPEUTICS, INC.
45 WIGGINS AVENUE
(Street)
BEDFORD MASSACHUSETTS 01730
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF MEDICAL OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/03/2026S(1)5,907D$28.9501(2)21,691D
Common Stock08/03/2026S(1)1,269D$29.4539(3)20,422D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.36 to $29.35 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.36 to $29.54 per share, inclusive.
/s/ Jonathan Allan, Attorney-in-Fact08/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR